Opens in a new tab or window The randomized phase III AALL1731 trial presented at the American Society of Hematology annual meeting showed that adding the bispecific T-cell engager blinatumomab ...

Bargou et al. assessed the efficacy of blinatumomab—an antibody with dual specificity for CD19 and CD3 antigens—in patients with non-Hodgkin lymphoma who relapsed after standard treatments.

12, 2024 (HealthDay News) -- For patients with newly diagnosed, standard-risk B-cell acute lymphoblastic leukemia (ALL) with an average or high risk for relapse, adding blinatumomab to combination ...

Next, he turns to a study of blinatumomab (BLIN) in pediatric ALL, which was presented during the ASH plenary session. BLIN improved outcomes for children with standard-risk B-cell ALL (B-ALL ...

SAN DIEGO -- Children with newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL) lived significantly longer without disease recurrence when they received the bispecific T-cell engager ...